NovoCure Limited (NVCR)
NASDAQ: NVCR · IEX Real-Time Price · USD
+0.84 (3.77%)
At close: May 24, 2024, 4:00 PM
+0.01 (0.04%)
After-hours: May 24, 2024, 7:35 PM EDT

NovoCure Statistics

Total Valuation

NovoCure has a market cap or net worth of $2.49 billion. The enterprise value is $2.21 billion.

Market Cap 2.49B
Enterprise Value 2.21B

Important Dates

The last earnings date was Thursday, May 2, 2024, before market open.

Earnings Date May 2, 2024
Ex-Dividend Date n/a

Share Statistics

NovoCure has 107.61 million shares outstanding. The number of shares has increased by 1.51% in one year.

Shares Outstanding 107.61M
Shares Change (YoY) +1.51%
Shares Change (QoQ) +0.34%
Owned by Insiders (%) 9.26%
Owned by Institutions (%) 84.96%
Float 98.03M

Valuation Ratios

PE Ratio n/a
Forward PE 909.09
PS Ratio 4.74
Forward PS 4.43
PB Ratio 6.93
P/FCF Ratio n/a
PEG Ratio -0.47
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 4.21
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 6.26, with a Debt / Equity ratio of 1.66.

Current Ratio 6.26
Quick Ratio 5.99
Debt / Equity 1.66
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage 5.12

Financial Efficiency

Return on equity (ROE) is -50.30% and return on invested capital (ROIC) is -22.43%.

Return on Equity (ROE) -50.30%
Return on Assets (ROA) -16.90%
Return on Capital (ROIC) -22.43%
Revenue Per Employee $361,775
Profits Per Employee -$132,651
Employee Count 1,453
Asset Turnover 0.46
Inventory Turnover 3.57


In the past 12 months, NovoCure has paid $20.44 million in taxes.

Income Tax 20.44M
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -71.00% in the last 52 weeks. The beta is 0.49, so NovoCure's price volatility has been lower than the market average.

Beta (1Y) 0.49
52-Week Price Change -71.00%
50-Day Moving Average 15.42
200-Day Moving Average 16.01
Relative Strength Index (RSI) 71.94
Average Volume (30 Days) 1,390,063

Short Selling Information

The latest short interest is 5.64 million, so 5.24% of the outstanding shares have been sold short.

Short Interest 5.64M
Short Previous Month 5.64M
Short % of Shares Out 5.24%
Short % of Float 5.75%
Short Ratio (days to cover) 5.05

Income Statement

In the last 12 months, NovoCure had revenue of $525.66 million and -$192.74 million in losses. Loss per share was -$1.80.

Revenue 525.66M
Gross Profit 393.30M
Operating Income -214.14M
Pretax Income -172.30M
Net Income -192.74M
EBITDA -203.08M
EBIT -214.14M
Loss Per Share -$1.80
Full Income Statement

Balance Sheet

The company has $873.75 million in cash and $595.26 million in debt, giving a net cash position of $278.49 million or $2.59 per share.

Cash & Cash Equivalents 873.75M
Total Debt 595.26M
Net Cash 278.49M
Net Cash Per Share $2.59
Equity / Book Value 359.36M
Book Value Per Share 3.34
Working Capital 842.48M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$88.18 million and capital expenditures -$32.79 million, giving a free cash flow of -$120.97 million.

Operating Cash Flow -88.18M
Capital Expenditures -32.79M
Free Cash Flow -120.97M
FCF Per Share -$1.13
Full Cash Flow Statement


Gross margin is 74.82%, with operating and profit margins of -40.74% and -36.67%.

Gross Margin 74.82%
Operating Margin -40.74%
Pretax Margin -32.78%
Profit Margin -36.67%
EBITDA Margin -38.63%
EBIT Margin -40.74%
FCF Margin -23.01%

Dividends & Yields

NovoCure does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -1.51%
Shareholder Yield -1.51%
Earnings Yield -7.74%
FCF Yield -4.86%
Dividend Details

Analyst Forecast

The average price target for NovoCure is $39.50, which is 70.63% higher than the current price. The consensus rating is "Buy".

Price Target $39.50
Price Target Difference 70.63%
Analyst Consensus Buy
Analyst Count 8
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) -14.77%
Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a


NovoCure has an Altman Z-Score of 1.42 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score 1.42
Piotroski F-Score 2